Short answer
GeneDx Holdings Corp. (WGS) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026 scheduled for release August 3, 2026.
GeneDx Holdings Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 scheduled for release August 3, 2026
- Press release and earnings presentation furnished as Exhibits 99.1 and 99.2
- Conference call planned for investor discussion of quarterly financial results
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $114.4M, up 11% YoY, with exome/genome revenue $100.3M, up 17%
- Exome/genome volumes rose 32% YoY to 30,785 tests, supporting GeneDx’s shift toward higher-growth genomic testing
- Adjusted net income reached $0.4M versus a $17.7M GAAP loss, while adjusted gross margin improved to 70%
- Full-year guidance reaffirmed at $475–$490M revenue, at least 30% volume growth, and positive adjusted net income
- Liquidity strengthened to approximately $188M pro forma through a $50M Blackstone term-loan increase and approximately $5M equity placement at $61 per share
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GeneDx Holdings Corp. 8-K filings
Get the next WGS 8-K as it lands
Follow WGS for push alerts, or ask the research agent what this filing means.